Similarly, another analysis demonstrated that rtCGM was likely to be cost-effective compared with SMBG in a type 2 diabetes population receiving insulin therapy, with HbA1c reduction and QoL benefit from reduced fingerstick testing being the main drivers of the outcomes observed [110]. Here, INS is linked to type 2 diabetes mellitus.